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Key questions
What is already know about the subject?
 ► Women with ST-segment elevation myocardial in-
farction (STEMI) have reportedly worse outcomes 
than men and microvascular pathology has been 
postulated as a potential mechanism.
 ► Findings from non-invasive imaging studies are 
conflicting, some report smaller infarcts in women 
while others report no sex differences.
 ► Previous studies did not use MRI methods to detect 
myocardial haemorrhage (microvascular destruc-
tion) and most acquired MRI at a single time point.
What does this study add?
 ► There were no sex differences in acute microvascu-
lar reperfusion injury with index of microcirculatory 
resistance, or on MRI.
 ► Women had fewer anterior myocardial infarcts and 
were prescribed beta-blockers at discharge less of-
ten than men.
How might this impact on clinical practice?
 ► The hypothesis of sex differences in acute micro-
vascular injury for STEMI is not supported by this 
study.
 ► This study serves a reminder of sex differences in 
post-MI care in contemporary practice, and the need 
to reduce sex imbalance in management.
ABSTRACT
Objectives We aimed to assess for sex differences in 
invasive parameters of acute microvascular reperfusion 
injury and infarct characteristics on cardiac MRI after ST-
segment elevation myocardial infarction (STEMI).
Methods Patients with STEMI undergoing emergency 
percutaneous coronary intervention (PCI) were prospectively 
enrolled. Index of microcirculatory resistance (IMR) and 
coronary flow reserve (CFR) were measured in the culprit 
artery post-PCI. Contrast-enhanced MRI was used to assess 
infarct characteristics, microvascular obstruction and 
myocardial haemorrhage, 2 days and 6 months post-STEMI. 
Prespecified outcomes were as follows: (i) all-cause death/
first heart failure hospitalisation and (ii) cardiac death/non-
fatal myocardial infarction/urgent coronary revascularisation 
(major adverse cardiovascular event, MACE) during 5- year 
median follow-up.
Results In 324 patients with STEMI (87 women, mean 
age: 61 ± 12.19 years; 237 men, mean age: 59 ± 11.17 
years), women had anterior STEMI less often, fewer 
prescriptions of beta-blockers at discharge and higher 
baseline N-terminal pro-B-type natriuretic peptide levels 
(all p < 0.05). Following emergency PCI, fewer women 
than men had Thrombolysis in Myocardial Infarction (TIMI) 
myocardial perfusion grades ≤ 1 (20% vs 32%, p = 0.027) 
and women had lower corrected TIMI frame counts (12.94 
vs 17.65, p = 0.003). However, IMR, CFR, microvascular 
obstruction, myocardial haemorrhage, infarct size, 
myocardial salvage index, left ventricular remodelling and 
ejection fraction did not differ significantly between sexes. 
Female sex was not associated with MACE or all-cause 
death/first heart failure hospitalisation.
Conclusion There were no sex differences in microvascular 
pathology in patients with acute STEMI. Women had less 
anterior infarcts than men, and beta-blocker therapy at 
discharge was prescribed less often in women.
Trial registration number NCT02072850.
InTROduCTIOn
Ischaemic heart disease is the leading cause 
of death and disability worldwide.1 Although 
many studies have reported worse outcomes 
in women after ST-segment elevation myocar-
dial infarction (STEMI),2 3 the results are 
conflicting.4 5
Confounders, including older age6 and 
comorbidities,7 particularly diabetes mellitus,8 
and renal insufficiency,3 6 may contribute 
to excess mortality in women post-STEMI. 
Another confounder is longer symptom to 
reperfusion times in women6 8–10 purport-
edly attributable to women underestimating 
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Figure 1 Consort flow diagram of the study. STEMI, ST-segment elevation myocardial infarction.
their cardiovascular risk or misinterpreting the symptoms 
which may be atypical in nature.11 Sex disparity in guide-
line-directed pharmacological2 and invasive reperfusion 
treatments has also been reported.3 10–12 Reducing sex 
imbalance in management and outcomes post-STEMI, 
and identifying potential mechanistic explanations, is 
emphasised in guideline recommendations.2 13
Findings from previous studies on sex and infarct size 
assessed by MRI are conflicting; some report smaller 
infarct size and greater myocardial salvage in women4 
while others reported no sex differences.6–8 14 A previous 
study using single-photon emission CT also observed 
better myocardial salvage after primary percutaneous 
coronary intervention (PCI) in women.5 Limitations of 
these studies include not using specific MRI methods to 
detect myocardial haemorrhage (a consequence of severe 
microcirculatory injury) and the acquisition of MRI at a 
single early time point post-STEMI in most,6–8 14 but not 
all, studies.4 This is relevant since the size of infarction 
evolves dynamically post-STEMI. Furthermore, patients 
included in some studies were pooled from multiple 
randomised trials.5 8
Microvascular dysfunction has been postulated as a 
potential mechanism for worse outcomes in women.8 
We investigated sex associations with the incidence, 
nature and timecourse of reperfusion injury in patients 
after an acute STEMI using invasive measures of micro-
vascular function acutely, and serial assessments with 
copyright.
 o
n
 Septem
ber 16, 2019 at University of G
lasgow. Protected by
http://openheart.bmj.com/
O
pen Heart: first published as 10.1136/openhrt-2018-000979 on 29 April 2019. Downloaded from
 
3Maznyczka AM, et al. Open Heart 2019;6:e000979. doi:10.1136/openhrt-2018-000979
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Table 1 Baseline characteristics
Characteristics* Women (n=87) Men (n=237) P value
Age (years), mean±SD 61.18±12.19 58.61±11.17 0.074*
Current smoker, n (%)
BMI (kg/m2), median (IQR)
57 (66)
28.50
(25.10–32.30)
139 (59)
28.30
(25.78–31.20)
0.262†
0.664‡
  BMI <25 (kg/m2), n (%)
  25≤BMI<30 (kg/m2), n (%)
  BMI≥30 (kg/m2), n (%)
18 (21)
29 (33)
40 (46)
44 (19)
112 (47)
81 (34)
0.069†
Hypertension, n (%) 32 (37) 73 (31) 0.308†
Hypercholesterolaemia, n (%) 28 (32) 66 (28) 0.446†
Diabetes mellitus, n (%) 8 (9) 26 (11) 0.644†
Previous MI, n (%) 5 (6) 20 (8) 0.421†
Previous PCI, n (%) 2 (2) 16 (7) 0.171§
Pre-infarct angina, n (%) 9 (10) 31 (13) 0.507†
Social deprivation status, n (%): 
  I
  II
  III
  IV
  V
31 (36)
16 (19)
16 (19)
11 (13)
12 (14)
81 (35)
53 (23)
38 (16)
39 (17)
23 (10)
0.750†
Presenting HR (bpm), median (IQR) 80.00
(67.50–91.00)
76.00
(65.00–87.00)
0.092‡
Presenting BP <90/60 (mm Hg), n (%) 14 (16) 21 (9) 0.063†
Ventricular fibrillation/tachycardia, n (%) 8 (9) 14 (6) 0.297†
Symptom to reperfusion time (min), median (IQR) 172.50
(122.00–316.00)
174.00
(119.00–314.00)
0.746‡
Symptom to reperfusion time >6 hours, n (%) 16 (20) 41 (18) 0.840†
Door-to-balloon time (min), median (IQR) 20.00
(16.00–23.00)
19.00
(16.00–24.00)
0.477‡
Killip class, n (%):
  I
  II
  III/IV
65 (75)
15 (17)
7 (8)
168(71)
53 (22)
16 (7)
0.584†
Reperfusion strategy, n (%):   0.458§
Primary PCI 83 (95) 219 (92)  
Thrombolysis (failed/successful) 4 (5.2) 18 (8.8)  
Aspiration thrombectomy, n (%) 57 (66) 179 (76) 0.073†
Glycoprotein IIbIIIa inhibitor, n (%) 82 (94) 215 (91) 0.307†
Medications at discharge: 
ACE-I or ARB, n (%) 85 (98) 235 (99) 0.293†
Beta-blocker, n (%) 79 (91) 229 (97) 0.032†
Statin, n (%) 87 (100) 237 (100)  
Aspirin, n (%) 86 (99) 237 (100) 0.098†
Clopidogrel, n (%)
Ticagrelor, n (%)
86 (99)
1 (1)
235 (99)
2 (1)
0.799†
Blood results on admission: 
Anaemia, n (%) 17 (20) 41 (17) 0.641†
eGFR ≥60 (mL/min/1.73 m2), n (%)
30≤eGFR<60 (mL/min/1.73 m2), n (%)
eGFR <30 (mL/min/1.73 m2), n (%)
76 (87)
11 (13)
0
222 (94)
14 (6)
0
0.059†
Continued
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Characteristics* Women (n=87) Men (n=237) P value
C-reactive protein, mg/L, median (IQR) 4.00
(2.00–9.00)
3.00
(2.00–7.00)
0.063‡
Peak troponin T, ng/L, median (IQR) 1334.00
(83.60–3548.00)
1944.50
(165.40–5437.50)
0.113‡
N-terminal pro-B-type natriuretic peptide, median (IQR) 1175.00
(627.50–2285.50)
701.50
(309.00–1456.00)
0.009‡
Blood results at 6 months post-STEMI 
N-terminal pro-B-type natriuretic peptide, median (IQR) 230.50
(97.00–510.50)
154.00
(73.00–337.00)
0.144‡
Presenting HR was available in 321 subjects. Symptom-to-reperfusion time was available in 304 subjects. Door-to-balloon time was available 
in 305 subjects. eGFR was available in 323 subjects. C-reactive protein was available in 316 subjects. Peak troponin was available in 313 
subjects. N-terminal pro-B-type natriuretic peptide results were available in 139 subjects on admission and 171 subjects at 6 months. 
Results of interleukin 6 were available in 139 subjects on admission and 171 subjects at 6 months. Information on anaemia was available in 
324 subjects and was defined as haemoglobin<130 g/L in men or <115 g/L in women.
*Student’s t-test.
†χ2 test.
‡Mann-Whitney U test.
§Fisher’s exact test.
ACE-I, ACE inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration 
rate; HR, heart rate; MI, myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction.
Table 1 Continued
multiparametric contrast-enhanced MRI.15 We also aimed 
to assess the prognostic implications on left ventricular 
(LV) surrogate outcomes revealed by MRI at 6 months 
and health outcomes in the longer term.
MeTHOds
study population
We performed a retrospective analysis of a prospec-
tively collected cohort of patients with acute STEMI in 
a regional cardiac centre from July 2011 to November 
2012. Consecutive, unselected patients with STEMI were 
screened for inclusion in the study and patients with 
MRI contraindications were excluded. The study was 
approved by the National Research Ethics Service (refer-
ence 10-S0703-28).
Sociodemographic status was identified from postcodes 
at the time of enrolment into the study, using the Scottish 
Index of Multiple Deprivation (SIMD) tool. The first and 
fifth SIMD quintiles contain the 20% most deprived and 
least deprived postal zones in Scotland, respectively.
Invasive physiology, angiographic and eCG measures of 
microvascular injury
Index of microcirculatory resistance (IMR) was meas-
ured in the culprit coronary artery using a coronary 
guidewire with a pressure sensor and temperature 
sensor (Abbott Vascular, Santa Clara, CA, USA) at 
the end of primary PCI or rescue PCI, as previously 
described.15 IMR is defined as distal coronary pressure 
multiplied by mean transit time of a bolus of saline at 
room temperature, during maximal coronary hyper-
aemia (induced by 140 µg/kg/min of intravenous 
adenosine preceded by an intracoronary bolus of 200 
µg of nitrate).15 Coronary flow reserve (CFR) is the 
mean transit time at rest divided by the mean transit 
time during hyperaemia.
Thrombolysis in Myocardial Infarction (TIMI) myocar-
dial perfusion grade and corrected TIMI frame count 
were evaluated at the end of the PCI procedure. If the 
infarct-related vessel was the left anterior descending 
artery (LAD), the frame count was divided by 1.7 to 
correct for longer vessel length. Complex plaques 
were defined as lesions ≥30% diameter stenosis with ≥2 
adverse features on a five-point plaque characterisation 
score comprising the following: presence of a filling 
defect/thrombus; ulceration; irregularity; TIMI flow <3, 
moderate/severe calcification or involvement of a bifur-
cation.16 Intraprocedural thrombotic events were defined 
as new or increasing thrombus, abrupt vessel closure, no 
reflow or slow reflow, or distal embolisation at any time 
during PCI.17 ST-segment resolution was assessed 60 min 
after reperfusion and was compared with ECGs obtained 
before coronary reperfusion.
Cardiac MRI
MRI was performed on a Siemens MAGNETOM Avanto 
(Erlangen, Germany) 1.5-Tesla scanner at 2 days post-
STEMI and 6 months later (figure 1). The imaging 
protocol (Supplementary Methods) included cine MRI 
with steady-state free precession, T2-mapping,18 native 
T1 mapping,19 T2*-mapping14 and delayed-enhancement 
phase-sensitive inversion-recovery pulse sequences.20 
The scan acquisitions were spatially co-registered and 
included different slice orientations to enhance diag-
nostic confidence.
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Table 2 ECG, invasive coronary physiology and 
angiographic characteristics
Women 
(n=87)
Men 
(n=237) P value
Angiography:
Number of diseased coronary 
arteries, n (%):
  1
  2
  3
48 (55)
27 (31)
12 (14)
126 (53)
72 (30)
39 (17)
0.842*
Culprit artery, n (%): LAD or left main
Right coronary artery
Circumflex
27 (31)/0
50 (58)
10 (12)
93 (39)/1 (0)
94 (39.7)
49 (21)
0.013*
TIMI flow grade pre-PCI ≤1, n (%) 65 (75) 162 (68) 0.268*
TIMI flow grade post-PCI ≤2, n (%) 4 (5) 19 (8) 0.288*
TIMI frame count post-PCI, median 
(IQR)
12.94
(10.00–
18.62)
17.65
(10.00–
27.77)
0.003†
TIMI myocardial perfusion grade 
post-PCI, n (%):
≤1
≥2
 
17 (20)
70 (81)
 
76 (32)
161 (68)
0.027*
Plaque characteristics:
Culprit lesion plaque characterisation 
score, n (%):
≤Median (4)
>Median (4)
 
76 (87)
11 (13)
 
193 (81)
44 (19)
0.208*
Number of complex plaques in 
culprit/non-culprit coronary arteries, 
n (%):
≤1
≥2
 
65 (75)
22 (25)
 
180 (76)
57 (24)
0.818*
Intraprocedural thrombotic event 
occurrence, n (%)
8 (9) 25 (11) 0.721*
Invasive coronary physiology:
IMR (U), median (IQR) 23.10
(15.00–
41.00)
25.50
(15.33–
47.68)
0.199†
IMR >40(U), n (%) 21 (27) 60 (28) 0.771*
CFR, median (IQR) 1.50
(1.10–2.03)
1.60
(1.10–2.10)
0.427†
CFR≤2, n (%) 13 (17) 37 (18) 0.871*
ECG:
ST-segment resolution, n (%):
Complete, ≥70%
Incomplete, 30% to <70%
None, ≤30%
 
44 (51)
31 (36)
12 (14)
 
104 (44)
96 (41)
36 (15)
0.580*
TIMI frame count post-PCI was available in 322 subjects. IMR 
was available in 289 subjects. CFR was available in 286 subjects. 
Information on ST-segment resolution was available in 323 subjects.
*χ2Chi-square test.
†Mann-Whitney U test.
CFR, coronary flow reserve; IMR, Index of microcirculatory resistance; 
LAD, left anterior descending artery; PCI, percutaneous coronary 
intervention; TIMI, Thrombolysis in Myocardial Infarction.
Image analyses
The MRI analyses are described in detail in the Supple-
mentary Methods. The results of infarct characteristics 
are reported for the whole of the LV.
Infarct size, microvascular obstruction and myocardial 
haemorrhage
The presence of acute infarction was established based on 
abnormalities in cine wall motion, rest first-pass myocar-
dial perfusion and delayed-enhancement imaging in two 
imaging planes. The myocardial mass of late gadolinium 
was quantified using computer-assisted planimetry and 
the territory of infarction was delineated using a signal 
intensity threshold of >5 standard deviations (SDs above 
a remote reference region and expressed as a percentage 
of total LV mass.14 Late gadolinium enhancement and 
microvascular obstruction were expressed as % LV mass.
Microvascular obstruction was defined as a dark zone 
on late gadolinium enhancement imaging at least 1 min 
post-contrast injection that persisted within an area of late 
gadolinium enhancement at 15 min. On the T2* maps, 
a region of reduced signal intensity within the infarcted 
area, with a T2* value of <20 ms14 was considered to 
confirm the presence of myocardial haemorrhage.
Myocardial salvage
Myocardial salvage was calculated by subtraction of the 
infarct size at 6 months from the baseline area at risk.14 
The myocardial salvage index was calculated by dividing 
the myocardial salvage area by the initial area at risk.
LV remodelling
An increase in ≥20% LV end-diastolic volume (LVEDV) 
at 6 months from baseline was taken to reflect adverse LV 
remodelling.19
Clinical outcomes
The prespecified primary composite outcome was 
all-cause death or the first heart failure hospitalisation 
following the initial admission. The second composite 
outcome was major adverse cardiovascular events 
(MACE) including cardiac death, non-fatal myocardial 
infarction (MI) or urgent coronary revascularisation 
(Supplementary Methods).
Statistical analyses
Statistical analyses were performed using SPSS (V.24.0, 
SPSS, IBM, Armonk, NY, USA) and MedCalc Statistical 
Software V.18 (MedCalc Software, Ostend, Belgium). 
Continuous variables were tested for normality using the 
Shapiro-Wilk test, and were presented as mean±SD, or 
median and interquartile range (IQR) as appropriate. 
Continuous and categorical between-group compari-
sons were based on χ2 and t-tests, respectively, unless 
indicated otherwise (tables 1–3). Associations between 
baseline covariates and MRI outcomes were evaluated 
using linear or logistic regression for continuous or 
categorical outcomes, respectively. Associations between 
baseline covariates and clinical outcomes were evalu-
ated using cox proportional hazards analyses. Non-sex 
(woman/ man) variables that were significant (p<0.05) 
were included in multivariable analyses to assess for 
associations between sex and parameters from the 
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Table 3 Cardiac MRI findings at 2 days and 6 months post-reperfusion in patients with STEMI
Female (n=87) Male (n=237) P value
MRI finding 2 days post-MI 
Infarct size (%LV mass), median (IQR)
LVEF%, mean±SD
15.90 [4.90–24.28)
56.5±9.8
16.50 [7.00–28.88)
53.2±9.5
0.141*
0.086†
LVESVi, mL/m2, median (IQR) 32.45 [23.40–40.00) 36.30 [27.40–46.30) <0.0001*
LVEDVi, mL/m2, median (IQR) 70.80 [63.70–80.60) 80.60 [72.53–91.58) <0.0001*
Microvascular obstruction present, n (%) 37 (43) 127 (54) 0.078‡
Microvascular obstruction extent (%LV mass), mean±SD 1.96±3.95 3.25±5.32 0.039*
Myocardial haemorrhage, n (%) 17 (29) 85 (45) 0.032‡
T1 remote zone (ms), mean±SD 968.46±24.97 958.74±24.64 0.003†
T1 infarct zone, (ms), mean±SD 1105.40±52.39 1091.20±51.04 0.042†
T1 core zone, (ms), mean±SD 1001.05±74.43 995.68±51.18 0.615†
T2 remote zone (ms), mean±SD 50.07±2.11 49.62±2.04 0.088†
T2 infarct zone (ms), mean±SD 62.45±4.91 63.04±5.22 0.356†
T2 core zone (ms), mean±SD 53.10±4.68 54.15±4.87 0.204†
  MRI finding 6 months post-MI 
Myocardial salvage index (%LV mass), median (IQR)
Infarct size (%LV mass), median (IQR)
64.20 [47.55–87.15)
9.70 [3.45–17.63)
60.40 [43.80–82.30)
12.10 [4.40–19.90)
0.169*
0.156*
LVEF% at 6 months, mean±SD 63.93±9.13 61.15±9.41 0.025†
LVESVi at 6 months, mL/m2, median (IQR) 26.55 [18.70–33.20) 31.50 [22.68–40.93) <0.0001*
LVEDVi at 6 months, mL/m2, median (IQR) 74.25 [63.60–80.80) 83.70 [72.75–94.55) <0.0001*
Change in LVEDVi (6 months compared with 2 days), 
median (IQR)
0.90 [−7.10 to 7.40) 2.25 [−5.55 to 9.60) 0.158*
Change in LVEDVi (6 months compared with 2 days≥20%), 
n (%)
5 (6) 15 (7) 0.872‡
Persistent myocardial haemorrhage, n (%): 
None/resolved
Persisting
43 (88)
6 (12)
121 (75)
41 (25)
0.054‡
T2 remote zone (ms), mean±SD 49.94±2.48 49.64±2.28 0.328†
T2 infarct zone (ms), mean±SD 56.41±3.95 56.05±4.24 0.512†
T2 core zone (ms), mean±SD 45.72±4.31 47.80±3.57 0.194†
LV volumes and ejection fraction on MRI at 2 days was available in 321 subjects. At 6 months, LV volumes were available in 294 subjects. 
Infarct size was available in 322 subjects on MRI at 2 days and 296 subjects at 6 months. Myocardial salvage index and LVEF at 6 months 
was available in 296 subjects. Presence/absence of microvascular obstruction was available in 324 subjects, extent of microvascular 
obstruction in 322 subjects, myocardial haemorrhage in 246 subjects and persistent myocardial haemorrhage in 211 subjects. T1 remote and 
infarct zone information was available in 288 subjects, and T1 core in 160 subjects. On MRI at 2 days, T2 remote/infarct zone information 
was available in 324 subjects, core zone in 192 subjects and at 6 months T2 remote, infarct, core zone was available in 297, 296 and 52 
subjects, respectively.
*Mann-Whitney U test.
†Student’s t-test.
‡χ2 test.
LV, left ventricular; LVEDVi, LV end-diastolic volume index; LVEF, left ventricular ejection fraction; LVESVi, LV end-systolic volume index; MI, 
myocardial infarction; STEMI, ST-segment elevation myocardial infarction.
angiographic, ECG and MRI analyses. Associations were 
expressed as odds ratios (OR), or hazard ratios (HR), 
with 95% confidence intervals (CIs). Predictors of late 
mortality (median 5-year follow-up) were assessed only 
in those patients who survived to hospital discharge 
(landmark survival analysis). Kaplan-Meier survival plots 
were constructed for visualisation and assessed using the 
log-rank test.
ResulTs
Baseline characteristics
Of 372 patients with acute STEMI who were assessed for 
eligibility, 324 (87%) patients were enrolled. Reasons for 
non-enrolment are detailed in figure 1. There were no 
patients who presented with myocardial infarction with 
non-obstructive coronary arteries. Women accounted 
for 27% (n=87) of the cohort and had a mean age of 
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61±12.19 years. Twenty five (29%) women were young 
(age <55 years), which did not differ significantly from 
the proportion of men in the study with age <55 years 
(n=84; 35%), p=0.260. Primary PCI was performed in 302 
(93%) subjects, the remainder had rescue PCI after failed 
thrombolysis (14; 4%) or PCI after successful thrombol-
ysis (8; 2%)).
Baseline demographic and clinical features of the 324 
patients with STEMI are shown in table 1. Women had 
higher baseline N-terminal pro-B-type natriuretic peptide 
levels, were less likely to have LAD territory infarctions 
and were less likely to have beta-blockers prescribed on 
discharge (all p<0.05). ECG, coronary physiology and 
angiographic characteristics are shown in table 2, and 
MRI findings are presented in table 3. The mean time 
between STEMI and baseline MRI was 2±1.90 days and 
did not differ between sexes (p=0.220).
Acute reperfusion outcomes in relation to sex
Compared with men, women were less likely to have 
TIMI myocardial perfusion grade ≤1 (20% vs 32%, OR: 
0.52, 95% CI: 0.28 to 0.97, p=0.040), after adjustment for 
estimated glomerular filtration rate (eGFR), reperfusion 
strategy (thrombolysis vs no thrombolysis), culprit artery 
territory (LAD/left main vs circumflex vs right coronary 
artery), age and ischaemic time. Consistent with this 
finding, female sex was a multivariable associate of lower 
corrected TIMI frame count (12.94 vs 17.65, β: −0.17, 
95% CI: −0.28 to −0.05, p=0.004). There were no sex 
differences in incomplete ST-segment resolution on the 
ECG (OR: 0.89, p=0.743) (table 4). IMR and CFR meas-
ured directly in the culprit artery were similar in women 
and men (table 2).
Infarct pathology and sex-specific associations
Microvascular obstruction and myocardial haemorrhage
Microvascular obstruction revealed by MRI 2 days after 
reperfusion occurred in 164 subjects (70%) (table 3). 
The proportions of women and men affected by micro-
vascular obstruction were similar (43% vs 54%, OR: 0.64, 
95% CI: 0.39 to 1.05, p=0.079). In multivariable models 
including infarct territory (which differed significantly 
between sexes), the association between sex and the pres-
ence of microvascular obstruction remained non-signifi-
cant (OR: 0.60, 95% CI: 0.35 to 1.02, p=0.060) (table 4).
Evaluable T2* maps on the baseline MRI were avail-
able in 246 patients (58 women, 67%; 188 men, 79%). 
Myocardial haemorrhage was present in 102 (41%) 
subjects, on baseline MRI, and occurred less frequently in 
women than men (29% vs 45%), but this difference was 
not significant after adjustment for eGFR, reperfusion 
strategy (thrombolysis vs no thrombolysis), culprit artery 
territory, age and ischaemic time (OR: 0.52, 95% CI: 0.26 
to 1.03, p=0.060). Evaluable T2* maps on the 6-month 
MRI were available in 251 patients (61 women, 70%; 
190 men, 55%). Persistent myocardial haemorrhage on 
the 6-month MRI occurred in 47 (22%) of subjects and 
was numerically lower in women (12% vs 25%), but this 
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Figure 2 (A) Kaplan-Meier curve for MACE-free survival, after initial hospitalisation to 5-year follow-up. (B) Kaplan-Meier 
curve for survival free from all-cause death or the first heart failure hospitalisation to 5-year follow-up. MACE, major adverse 
cardiovascular event.
difference was not statistically significant (OR: 0.48, 95% 
CI: 0.21 to 1.08, p=0.075).
Remote zone inflammation
Female sex was a multivariable associate of higher T1 
remote zone signal on baseline MRI (968.46 vs 958.74 
ms, β: 0.18, 95% CI: 0.06 to 0.30, p=0.004). After adjust-
ment for the same variables, T1 infarct zone signal was 
not associated with sex (β: 0.11, p=0.063). There were no 
sex differences in T1 core zone signal on baseline MRI, 
or T2 signal on MRI at baseline or at 6 months (table 4).
LV volumes and adverse remodelling
Adverse LV remodelling, defined as an increase in ≥20% 
LVEDV at 6 months from baseline, occurred in 6% of 
women and 7% of men (OR: 0.92, p=0.872). Women had 
smaller indexed LVEDVs than men 2 days (70.80 vs 80.60 
mL/m2, β: −0.26, 95% CI: −0.36 to −0.20, p<0.0001) and 6 
months post-MI (74.25 vs 83.70 mL/m2, β: −0.26, 95% CI: 
−0.37 to −0.15, p<0.0001). Women had smaller indexed 
LV end-systolic volumes than men 2 days (32.45 vs 36.30 
mL/m2, β: −0.17, 95% CI: −0.27 to –0.07, p=0.002) and 6 
months post-MI (26.55 vs 31.50 mL/m2, β: −0.19, 95% CI: 
−0.31 to −0.08, p<0.0001).
LVEF, Infarct size and myocardial salvage index
Infarct size, myocardial salvage and LV ejection fraction 
were similar in women and men at 2 days and 6 months 
post-MI (table 3).
Health outcomes
In the landmark survival analysis with median 5-year 
follow-up, female sex was not associated with either 
MACE (women n=10 [11.5%] vs men n=30 [14.5%], HR: 
0.92, 95% CI: 0.45 to 1.89, p=0.820), or all-cause death or 
first hospitalisation for heart failure postdischarge (n=11 
[13%] compared with men n=36 [15%], HR: 0.80, 95% 
CI: 0.41 to 1.57, p=0.520) (figure 2).
dIsCussIOn
We have undertaken a large, contemporary, prospec-
tive study of sex-based associations in acute reperfusion 
injury, infarct characteristics and long-term prognosis 
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after STEMI. Anterior MI was more common in men and 
beta-blockers were prescribed less often in women. We 
observed no sex differences in acute reperfusion injury 
assessed by IMR or CFR, but angiographically corrected 
TIMI frame count was lower and TIMI myocardial perfu-
sion grade was higher in women than men. On MRI 
performed 2 days and 6 months later, there were no differ-
ences in microvascular obstruction, myocardial haemor-
rhage, infarct size, myocardial salvage index, LV remod-
elling or LV function. 3 6Long-term health outcomes in 
women and men were similar.
Microvascular reperfusion injury in women post-sTeMI
The angiographic finding of lower corrected TIMI frame 
count and higher myocardial perfusion grade in women 
was a surprise finding, and perhaps suggests that PCI 
was less effective in women than men. Prior studies have 
reported that women were more likely to have pre-in-
farct angina than men4 5 implicating ischaemic precon-
ditioning as a plausible explanation.21 The comparatively 
low rates of pre-infarct angina, without sex differences 
(women 10% vs males 13%; p=0.507), do not implicate 
this explanation in our cohort. We considered whether 
sex differences in lesion plaque characteristics at the time 
of angiography may have contributed to the lower TIMI 
myocardial perfusion grade and higher corrected TIMI 
frame count in men. However, no sex differences were 
detected in culprit lesion plaque characterisation score, 
or total number of complex plaques (table 2). We also 
found no sex differences in intraprocedural thrombotic 
events, which is consistent with previous reports.17 In a 
previous study, male patients with STEMI had higher 
plaque burden than propensity-matched women, as 
revealed by virtual histology intravascular ultrasound22; 
however high-risk lesion characteristics such as thin cap 
fibroatheroma were similar in both sexes.22
Even though we observed angiographically lower 
corrected TIMI frame counts and higher TIMI myocar-
dial perfusion grades at the end of the PCI procedure 
in women than men, there were no sex differences in 
invasive coronary physiology measurements of acute 
microvascular reperfusion injury, that is, IMR and CFR. 
We considered whether this result could be explained by 
men in our cohort having more LAD territory infarcts. 
However, even when the analysis was restricted to patients 
with IMR measured in the LAD, there was still no sex 
difference in IMR.
The inconsistency between the acute angiographic 
and invasive coronary physiology observations might be 
explained by angiography-based techniques for assessing 
microvascular function having lower specificity and 
poorer interobserver and intraobserver reproducibility, 
largely related to dependence on volume of contrast dye 
injected or force of injection, coronary artery size and 
haemodynamic conditions. Even though corrected TIMI 
frame count measured in the LAD was divided by 1.7 to 
correct for the relatively longer vessel length, it is plau-
sible that the higher proportion of LAD infarcts in males 
may still have contributed to the higher corrected TIMI 
frame count in males. IMR has previously been shown to 
have better predictive utility for microvascular obstruc-
tion than angiographic parameters.23 The IMR and CFR 
results were consistent with the MRI findings. Further-
more, the CIs are narrow for the non-significant associ-
ations between sex and the presence of microvascular 
obstruction or myocardial haemorrhage, which suggests 
that type II statistical error was unlikely (table 4).
Microvascular reperfusion plays an important role in 
ameliorating adverse LV remodelling24 and prior liter-
ature suggests that LV remodelling is more favourable 
in women, potentially due to sex differences in modu-
lation of the ischaemia-induced apoptotic cascade.25 
In our cohort, LV remodelling was not significantly 
different between men and women. Furthermore, N-ter-
minal pro-B-type natriuretic peptide level at 6 months (a 
biomarker of adverse LV remodelling19) did not differ 
between women and men. We found that myocardial 
remote zone native T1 (a biomarker of inflammation and 
risk factor for adverse LV remodelling19) was higher in 
women. However, there were no sex differences in remote 
zone native T2. Taken together, the findings suggest that 
the sex differences in remote zone T1 may be explained 
by women generally having higher myocardial T1 values 
than men26 and not due to a higher degree of inflamma-
tion of the remote zone in women.
Our data contrast with those of Canali et al,4 who 
reported that women had more favourable microvascular 
obstruction extent, infarct size and myocardial salvage 
post-STEMI. Our study extends the findings of Canali et 
al4 by providing new information on coronary physiology 
acutely, myocardial haemorrhage at 2 days and 6 months, 
and long-term clinical outcomes.
In-hospital acute MI care and beta-blocker therapy
The door-to-balloon time, a measure of the efficiency 
of emergency in-hospital care for STEMI, was short and 
similar in women and men. Furthermore, in contrast to 
previous studies, ischaemic time (which is causally impli-
cated in the development of microvascular obstruction) 
was similar in women and men in our contemporary 
cohort. Other in-hospital treatments were also similar. 
On the other hand, beta-blocker therapy was prescribed 
less often in women at discharge. The reasons for this 
sex-based difference are unclear. Beta-blocker therapy 
notably with metoprolol may reduce reperfusion injury 
and improve prognosis (including in women),27 and 
beta-blocker therapy post-MI is recommended in prac-
tice guidelines.28 Previous studies have found that women 
were less likely than men to adhere effectively to chronic 
medications including after MI.29 The difference in beta-
blocker therapy serves another reminder of sex differ-
ences in post-MI care in contemporary practice.
limitations
This is an observational study, so causality cannot be 
inferred. The data are from a single centre, but it is still 
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likely to be representative of contemporary patients with 
STEMI in other centres. The study was not powered to 
demonstrate sex differences in clinical outcomes. We do 
not have information on medication adherence postdis-
charge and do not have information on the reason for 
beta-blockers being prescribed less often in women.
COnClusIOns
There were no sex differences in serial measures of micro-
vascular reperfusion injury from acute invasive coronary 
physiology and MRI performed 2 days and 6 months 
later. LV remodelling and health outcomes were also 
similar. Beta-blocker therapy at discharge was prescribed 
less often in women than men, and anterior MI was more 
common in men.
Contributors AM wrote the manuscript, statistically analysed the results and 
interpreted the data. DC coordinated the study, obtained informed consent in all of 
the participants, coordinated and analysed the MRI scans. He collected the clinical 
data, interpreted the results and contributed to the manuscript. IF contributed to 
study design and contributed to the manuscript. NS contributed to study design. 
AM assessed the source data for serious adverse events during follow-up that 
were potentially relevant to the prespecified health outcomes. KM contributed to 
the analysis of the clinical MRI scans in patients with STEMI and contributed to 
the manuscript. JC contributed to the analysis of the clinical MRI scans in patients 
with STEMI and performed the angiographic analysis. CB is PI for the research 
grant from the British Heart Foundation and Chief Investigator for the clinical study. 
CB conceived the idea for the study, obtained the funding and ethics approvals. 
He participated in patient recruitment, collected clinical data and interpreted the 
results. CB takes responsibility for the manuscript.
Funding This work was supported by the British Heart Foundation (BHF) (Centre of 
Research Excellence Award [RE/18/6134217], BHF Project Grant [PG/11/2/28474]), 
the National Health Service and the Chief Scientist Office. CB was supported by a 
Senior Fellowship from the Scottish Funding Council. PW is supported by a BHF 
Intermediate Fellowship [FS/12/62/29889]. AM is supported by a BHF Clinical 
Research Training Fellowship [FS/16/74/32573].
Competing interests CB: Research Grant—Significant; Based on an institutional 
agreement with the University of Glasgow, CB has acted as a consultant to 
Abbott, a manufacturer of diagnostic coronary guidewires. The company has 
offered a significant research grant in relation to a research project led by CB. The 
University of Glasgow holds a research agreement with Siemens Healthcare, which 
manufactured the MRI scanner used in this study. KO: Honoraria—Modest. KO has 
acted as consultant to Abbott.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
RefeRences
 1. Townsend N, Wilson L, Bhatnagar P, et al. Cardiovascular disease in 
Europe: epidemiological update 2016. Eur Heart J 2016;37:3232–45.
 2. Mehta LS, Beckie TM, DeVon HA, et al. American Heart Association 
cardiovascular disease in women and special populations 
Committee of the Council on clinical Cardiology, Council on 
epidemiology and prevention, Council on cardiovascular and stroke 
Nursing, and Council on quality of care and outcomes research. 
acute myocardial infarction in women: a scientific statement from the 
American Heart Association. Circulation 2016;133:916–47.
 3. Alabas OA, Gale CP, Hall M, et al. Sex differences in treatments, 
relative survival, and excess mortality following acute myocardial 
infarction: national cohort study using the SWEDEHEART registry. J 
Am Heart Assoc 2017;6:e007123.
 4. Canali E, Masci P, Bogaert J, et al. Impact of gender differences 
on myocardial salvage and post-ischaemic left ventricular 
remodelling after primary coronary angioplasty: new insights from 
cardiovascular magnetic resonance. Eur Heart J Cardiovasc Imaging 
2012;13:948–53.
 5. Mehilli J, Ndrepepa G, Kastrati A, et al. Gender and myocardial 
salvage after reperfusion treatment in acute myocardial infarction. J 
Am Coll Cardiol 2005;45:828–31.
 6. Tomey MI, Mehran R, Brener SJ, et al. Sex, adverse cardiac events, 
and infarct size in anterior myocardial infarction: an analysis of 
intracoronary abciximab and aspiration thrombectomy in patients 
with large anterior myocardial infarction (INFUSE-AMI). Am Heart J 
2015;169:86–93.
 7. Eitel I, Desch S, de Waha S, et al. Sex differences in myocardial 
salvage and clinical outcome in patients with acute reperfused ST-
elevation myocardial infarction: advances in cardiovascular imaging. 
Circ Cardiovasc Imaging 2012;5:119–26.
 8. Kosmidou I, Redfors B, Selker HP, et al. Infarct size, left ventricular 
function, and prognosis in women compared to men after 
primary percutaneous coronary intervention in ST-segment 
elevation myocardial infarction: results from an individual 
patient-level pooled analysis of 10 randomized trials. Eur Heart J 
2017;38:1656–63.
 9. Bugiardini R, Ricci B, Cenko E, et al. Delayed care and mortality 
among women and men with myocardial infarction. J Am Heart 
Assoc 2017;6:e005968.
 10. D'Onofrio G, Safdar B, Lichtman JH, et al. Sex differences 
in reperfusion in young patients with ST-segment-elevation 
myocardial infarction: results from the VIRGO study. Circulation 
2015;131:1324–32.
 11. Lichtman JH, Leifheit EC, Safdar B, et al. Sex differences in the 
presentation and perception of symptoms among young patients 
with myocardial infarction: evidence from the VIRGO study (variation 
in recovery: role of gender on outcomes of young AMI patients). 
Circulation 2018;137:781–90.
 12. Khera S, Kolte D, Gupta T, et al. Temporal Trends and Sex 
Differences in Revascularization and Outcomes of ST-Segment 
Elevation Myocardial Infarction in Younger Adults in the United 
States. J Am Coll Cardiol 2015;66:1961–72.
 13. Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the 
management of acute myocardial infarction in patients presenting 
with ST-segment elevation: the task Force for the management of 
acute myocardial infarction in patients presenting with ST-segment 
elevation of the European Society of cardiology (ESC). Eur Heart J 
2018;39:119–77.
 14. Eitel I, Desch S, Fuernau G, et al. Prognostic significance and 
determinants of myocardial salvage assessed by cardiovascular 
magnetic resonance in acute reperfused myocardial infarction. J Am 
Coll Cardiol 2010;55:2470–9.
 15. Carrick D, Haig C, Ahmed N, et al. Comparative prognostic utility 
of indexes of microvascular function alone or in combination in 
patients with an acute ST-segment-elevation myocardial infarction. 
Circulation 2016;134:1833–47.
 16. Keeley EC, Mehran R, Brener SJ, et al. Impact of multiple complex 
plaques on short- and long-term clinical outcomes in patients 
presenting with ST-segment elevation myocardial infarction (from 
the Harmonizing Outcomes With Revascularization and Stents in 
Acute Myocardial Infarction [HORIZONS-AMI] Trial). Am J Cardiol 
2014;113:1621–7.
 17. Schoos MM, Mehran R, Dangas GD, et al. Gender differences in 
associations between intraprocedural thrombotic events during 
percutaneous coronary intervention and adverse outcomes. Am J 
Cardiol 2016;118:1661–8.
 18. Verhaert D, Thavendiranathan P, Giri S, et al. Direct T2 quantification 
of myocardial edema in acute ischemic injury. JACC Cardiovasc 
Imaging 2011;4:269–78.
 19. Carrick D, Haig C, Rauhalammi S, et al. Pathophysiology of 
LV Remodeling in Survivors of STEMI: Inflammation, Remote 
Myocardium, and Prognosis. JACC Cardiovasc Imaging 
2015;8:779–89.
 20. Kellman P, Arai AE, McVeigh ER, et al. Phase-sensitive inversion 
recovery for detecting myocardial infarction using gadolinium-
delayed hyperenhancement. Magn Reson Med 2002;47:372–83.
 21. Ann SH, De Jin C, Singh GB, et al. Gender differences in plaque 
characteristics of culprit lesions in patients with ST elevation 
myocardial infarction. Heart Vessels 2016;31:1767–75.
 22. Bolognese L, Carrabba N, Parodi G, et al. Impact of microvascular 
dysfunction on left ventricular remodeling and long-term clinical 
outcome after primary coronary angioplasty for acute myocardial 
infarction. Circulation 2004;109:1121–6.
copyright.
 o
n
 Septem
ber 16, 2019 at University of G
lasgow. Protected by
http://openheart.bmj.com/
O
pen Heart: first published as 10.1136/openhrt-2018-000979 on 29 April 2019. Downloaded from
 
Open Heart
12 Maznyczka AM, et al. Open Heart 2019;6:e000979. doi:10.1136/openhrt-2018-000979
 23. Dargie HJ. Effect of carvedilol on outcome after myocardial 
infarction in patients with left-ventricular dysfunction: the Capricorn 
randomised trial. Lancet 2001;357:1385–90.
 24. Biondi-Zoccai GGL, Abate A, Bussani R, et al. Reduced post-
infarction myocardial apoptosis in women: a clue to their different 
clinical course? Heart 2005;91:99–101.
 25. Rosmini S, Bulluck H, Captur G, et al. Myocardial native T1 and 
extracellular volume with healthy ageing and gender. Eur Heart J 
Cardiovascular Imaging 2018;19:615–21.
 26. Carrick D, Haig C, Carberry J, et al. Microvascular resistance of the 
culprit coronary artery in acute ST-elevation myocardial infarction. 
JCI Insight 2016;1:e85768.
 27. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA 
guideline for the management of ST-elevation myocardial infarction: 
Executive summary: a report of the American College of cardiology 
Foundation/American Heart Association Task Force on practice 
guidelines. Circulation 2013;127:529–55.
 28. Eindhoven DC, Hilt AD, Zwaan TC, et al. Age and gender differences 
in medical adherence after myocardial infarction: Women do not 
receive optimal treatment - The Netherlands claims database. Eur J 
Prev Cardiol 2018;25:181–9.
 29. Ottani F, Galvani M, Ferrini D, et al. Prodromal angina limits 
infarct size. A role for ischemic preconditioning. Circulation 
1995;91:291–7.
copyright.
 o
n
 Septem
ber 16, 2019 at University of G
lasgow. Protected by
http://openheart.bmj.com/
O
pen Heart: first published as 10.1136/openhrt-2018-000979 on 29 April 2019. Downloaded from
 
